I totally understand what kind of job you had. I work at a Wally World distribution center. Started in shipping, loading about 3 to 4 full semi’s a day. Didn’t know how much weight I loaded. Then switched to non conveyable. When in dog food, I’d stack about 60k/lbs in 12 hours. That was MUCH easier than shipping. My first year, I struggled. Then I talked to my bro-in-law, who is a personal trainer, found and I started to do good. I was taking creatine and C4 prior to work, and took an Animal Pak with UniLiver every break, while eating protien every 3-4 hours. This brought me to Muscle for Life and The Books. I’m in maintenance department now, and are about to join a gym. I’ve been wanting to get the Legion multi’s and switch to Legion supplements. I’m about done reading BLS, and are gonna start the year one challenge. I’ve aready bought BBLS and Shredded Chef. I get excited every time I think about my goals.
A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was months in the nab-paclitaxel-gemcitabine group as compared with months in the gemcitabine group (hazard ratio for death, ; 95% confidence interval [CI], to ; P<). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was months in the nab-paclitaxel-gemcitabine group, as compared with months in the gemcitabine group (hazard ratio for disease progression or death, ; 95% CI, to ; P<); the response rate according to independent review was 23% versus 7% in the two groups (P<). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days.